Direct-Acting Oral Anticoagulants and Potential Inconsistencies with FDA-Approved Dosing for Non-Valvular Atrial Fibrillation: A Retrospective Real-World Analysis Across Nine US Healthcare Systems.

ABSTRACT:

Background

Direct-acting oral anticoagulants (DOACs) are recommended to reduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). However, DOAC dosing inconsistent with FDA-approved product labels is common and associated with poor clinical outcomes.

Objectives

Identify DOAC dosing inconsistent with FDA-approved product labels in ambulatory care patients with NVAF; identify variables associated with dosing lower and higher than label.

Design

Retrospective analysis using electronic health records from nine US healthcare systems.

Patients

Adults with NVAF receiving DOAC therapy in 2022.

Main measures

Rates of label-inconsistent dosing; multivariable regression analysis to identify demographic and clinical variabl

SUBMITTER: DeLor B 

PROVIDER: S-EPMC11914546 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature